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ABSTRACT
Objectives: To outline the epidemiological profile of diabe-
tic patients with Charcot arthropathy affecting the midfoot 
alone or extending from the midfoot to the hindfoot; To 
assess the results from the treatment that these patients 
undergo, according to a preestablished protocol, over the 
medium term. Methods: We retrospectively evaluated 88 
patients (110 extremities) with Charcot arthropathy of the 
midfoot. The minimum follow-up period was 12 months. 
We included 45 patients with Charcot arthropathy affecting 
the tarsal-metatarsal joints (51%); 20 patients in whom 
the talonavicular, calcaneocuboid and subtalar joints were 
affected (23%); and 23 patients in whom both the midfoot 
and hindfoot were affected (26%), as described by Brodsky 
and Trepman. We defined the treatment as successful when 
a functional foot was preserved; and unsuccessful when 
Rev Bras Ortop. 2012;47(5):616-25
INTRODUCTION
Diabetes is a chronic disease with high prevalence 
in modern society and is closely associated with obe-
sity(1,2). It constitutes a public health problem because 
it is now of epidemic proportions worldwide, with 
171 million people affected in the year 2000(3).
Introduction of insulin in treating the disease has 
provided improvements in blood glucose control 
and has increased patients’ survival. Consequently, 
late-stage complications of diabetes that were only 
rarely observed in the past have become noted with 
greater frequency(4,5).
Peripheral neuropathy is the main cause of late 
complications in the feet of diabetic patients. De-
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the foot was amputated. Results: From treating Charcot 
arthropathy primarily involving the midfoot were satisfac-
tory in the cases of 75 patients (85%) treated according to 
our protocol. For the patients with severe lesions affecting 
both the midfoot and the hindfoot, a greater number of 
complex operations (i.e. arthrodesis) were needed in order 
to obtain the same overall rate of satisfactory results. The 
osteoarticular lesions originating in the midfoot probably 
extended progressively to the hindfoot because of delayed 
diagnosis with inadequate early treatment. Conclusion: It 
was possible to preserve a functional extremity in 85% 
of the patients. Severe lesions involving the midfoot and 
extending to the hindfoot required a greater number of 
surgical procedures to treat them.
Keywords – Arthropathy, Neurogenic; Diabetes; Foot; 
Amputation
formities resulting from intrinsic muscle paralysis, 
loss of protective muscle paralysis and destruction of 
bones and joints of the foot and ankle are the three 
most common occurrences that predispose towards 
appearance of pressure ulcers on the feet(6).
Charcot arthropathy, which affects the feet and ank-
les, is becoming a relatively common problem among 
diabetic patients, especially those in whom the disease 
has been developing for more than 10 years(1,7).
Destruction and disarrangement of the osteoarti-
cular architecture of the foot may create deformities 
and instabilities, with subsequent appearance of bone 
prominences, particularly when the lesion affects the 
midfoot and provokes collapse of the medial arch(8-11).
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not come in person for reevaluation was gathered 
from the institution’s medical files. These files con-
tained their histories, data on clinical and laboratory 
tests, and photographs and radiographs of the affected 
extremities. The mean age of these 35 female patients 
and 53 male patients at the start of their outpatient 
follow-up was 59 years (range from 32 to 87 years). 
The mean length of follow-up was 21 months.
Type II diabetes was more prevalent, affecting 
80 of the 88 patients (91%). Fifty-five patients were 
making regular use of insulin (62%). The mean time 
that had elapsed between the appearance of the first 
symptoms of diabetes and the start of Charcot arthro-
pathy was 12 years (ranging from zero and 44 years). 
Among the eight patients (9%) with type I diabetes, 
the mean interval between the diagnosing of the dise-
ase and the start of symptoms of Charcot arthropathy 
was 19 years, while in the group of patients with type 
II diabetes, this mean interval was 11 years.
Twenty-eight patients (32%) were smokers and 24 
(27%) were drinkers. An association between these 
two habits was found in 16 patients (18%). Smoking 
and drinking were defined in accordance with the cri-
teria of the World Health Organization (WHO)(14,15).
The presence of some degree of vascular disease, 
even without any apparent clinical repercussion, was 
detected in 41 of the 88 patients (47%). The crite-
ria for evaluating this disorder involved comparative 
palpation of the anterior and posterior distal tibial 
pulses between the two extremities and observation of 
the capillary filling time, which was considered to be 
normal when this took not more than three seconds.
At the time when these 88 patients arrived at our 
outpatient clinic, the anatomical location of the le-
sions was assessed based on radiographic images and 
presented the following distribution: tarsometatarsal 
joints (TM) (Brodsky type I) in 45 patients (51%); 
talonavicular (TN), calcaneocuboid (CC) and subtalar 
(ST) joints (Brodsky type II) in 20 (23%); and mi-
dfoot joints with extension to the hindfoot (Trepman 
type IV) in 23 patients (26%) (Table 1).
The stage of evolution of the disease was also 
evaluated at the start of the outpatient follow-up, in 
accordance with the Eichenholtz classification(16). The 
following distribution was observed among the 88 
patients: in 41 (47%), the lesion was at the initial 
phase of bone fragmentation (type I); in 17 (19%), in 
the hypertrophic phase of consolidation (type II); and 
in 30 (34%), in the late phase of sequelae (type III).
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Early diagnosis of Charcot arthropathy and im-
mediately starting treatment may be decisive in the 
evolution of the disease, with regard to preservation 
or amputation of the foot(6).
The aims of the present study were: 1) to outline 
the epidemiological profile of diabetic patients with 
Charcot arthropathy exclusively affecting the midfoot 
or extending from the midfoot to the hindfoot; and 2) 
to evaluate, over the medium term, the result from the 
treatment that these patients undergo, in accordance 
with a preestablished protocol. In this study, we defi-
ned success as preservation of a functional foot and 
failure as amputation of the foot. Our hypothesis was 
that, in our setting, the diagnosis of Charcot arthro-
pathy is made late, and that this delays the start of 
treatment and may contribute negatively towards the 
outcome. We believe in the hypothesis that systemati-
zation of orthopedic treatment may contribute towards 
reducing the frequency of amputations.
SAMPLE AND METHODS
Epidemiological factors
Over a 12-year period, from March 1998 to June 
2011, 580 diabetic patients were treated at the spe-
cialized outpatient clinic for foot and ankle surgery 
of the Department of Orthopedics and Traumatology 
of our institution. Among these, 174 patients (30%) 
(206 lower-limb extremities) presented Charcot ar-
thropathy affecting the foot and ankle. For this study, 
we selected the diabetic patients with peripheral neu-
ropathy, loss of protective sensitivity of the extremity 
and Charcot arthropathy that exclusively affected the 
Lisfranc joint (Brodsky type I)(12), talonavicular, cal-
caneocuboid and subtalar joints (Brodsky type II) or 
midfoot joints with extension to the hindfoot (Trep-
man type IV)(13). In this series, we excluded patients 
whose minimum follow-up was less than 12 months 
and those whose medical files did not contain suffi-
cient information for this study. In this manner, our 
final sample was formed by 88 patients, of whom 22 
were affected bilaterally, thus totaling 110 extremities.
The patients were invited to come for a clinical 
reevaluation between March and December 2010. 
Twenty-one of these 88 patients (24%) responded 
to the call. These patients were interviewed and un-
derwent physical and radiographic examinations. The 
information on the other 67 patients (76%) who could 
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Figure 1 – Profile of the right foot showing diffuse edema and collapse of 
the medial plantar arch (4A). Lateral radiograph of the foot (4B) showing 
lesion affecting both the midfoot and the hindfoot (Trepman type IV). Diffuse 
osteopenia and multiple fractures-dislocations can be seen, involving the 
tarsal bones, which are typical lesions of Eichenholtz evolutional stage I. 
The arrow indicates joint dissociation at the level of the Chopart joint (TN 
and CC). Note also the collapse of the arch and the equinus position of the 
hindfoot bone (talus and calcaneus), shown in the dotted circle. 
Source: SAME ISCMSP.
Table 1 – Profile of the 88 patients in the study regarding the risk factors 
associated with type I and II diabetes. Source: SAME ISCMSP.
Factor evaluated Value
Mean age 59 years
Bilaterality 22 (25%)
Type I diabetes 8 (9%)
Type II diabetes 80 (91%)
Mean time elapsed between diagnosing of diabetes 
and appearance of Charcot arthroplasty 12 anos
Insulin use 55 (62%)
Smoking 28 (32%)
Drinking 24 (27%)
Smoking and drinking 16 (18%)
Vascular disease 41 (47%)
treatment protocol for Charcot arthropathy
In our institution, the protocol for treating Charcot 
arthropathy of the midfoot is based and guided by the 
stage of evolution of the disease(16). Active lesions in the 
phase of bone fragmentation (stage I) are characterized 
clinically by edema, hyperemia and hyperthermia 
of the foot and ankle. On simple radiographs of the 
affected foot, we observed osteopenia, periarticular 
fragmentation, subluxation or even joint dislocation 
(Figure 1). The patients were treated by means of total 
contact plaster casts (TCC) until the inflammatory 
phase had been resolved(17,18). The transition from 
the fragmentation phase to the coalescence phase
(stage II) was determined by the clinical observation of 
reductions of the edema, temperature and hyperemia. On 
radiographs, we checked for the presence of absorption, 
bone consolidation and bone sclerosis(12,19) (Figure 2). 
For the patients who reached the coalescence phase, 
the TCC was replaced by an orthotic boot made of 
AFO polypropylene extending from mid-calf to the 
foot, together with use of protective footwear made-to-
measure for extra-deeply insensitive feet. This orthosis 
was then kept in use until complete bone consolidation 
had been achieved (Eichenholtz phase III), characterized 
by complete absence of inflammatory signs in physical 
examinations and by the presence of radiographic 
consolidation (bone callus and trabeculae crossing the 
fracture lines) (Figure 3).
When bone consolidation had been achieved, the 
patient was instructed to use protective footwear for 
extra-deeply insensitive feet. Made-to-measure inso-
les were prescribed with the aim of accommodating 
residual deformities resulting from skewed consoli-
dation, especially in cases with a collapsed medial 
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plantar arch or presence of plantar bone prominences, 
which are generally located in the midfoot region. If 
the foot or ankle was seen to present instability after 
the consolidation phase, we indicated associated use 
of an orthotic boot covering from mid-calf to the foot 
on a permanent basis.
We indicated surgery for removing plantar bone 
saliencies (exostectomy) when the foot was in a stable 
condition, with adequate circulation, but there may be 
plantar prominences located in the midfoot (Schon 
grades Band C)(10) with concomitant formation of 
recurrent ulcers that are refractory to conservative 
treatment (debridement and TCC)(20).
In cases in which the residual deformity is very ac-
centuated, or when there is major residual deformity, 
extending secondarily to the hindfoot (Trepman grade 
IV)(13), or it is impossible to fit the foot into a molded 
orthotic boot made of AFO polypropylene, recons-
tructive surgery (modeling arthrodesis) is indicated 
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Figure 2 – Profile of the right foot of the same patient as in Figure 1, showing 
reduction of the edema following treatment with TCC (5A). The collapse of 
the medial plantar arch is more evident. Lateral radiograph of the foot (5B) 
showing extensive area of bone neoformation (dotted circle) typical of Ei-
chenholtz evolutional stage II. Note the prominence of the head of the talus 
(arrow) in the plantar region of the midfoot, thus characterizing collapse of 
the medial arch and formation of a so-called blotter lesion.
Source: SAME ISCMSP.
Figure 3 – Profile of the right foot of the same patient as in Figures 1 and 2 
after completing the treatment with TCC, showing the plantigrade position of 
the foot, now without detectable edema but with marked collapse of the me-
dial arch (6A). Note also the prominence in the plantar region, characterizing 
the blotter appearance of the foot (arrow). Lateral radiograph of the foot (6B) 
with signs of bone consolidation, characteristic of Eichenholtz evolutional 
stage III. Note the persistence of a large bone prominence present in the 
plantar region of the midfoot (arrow), which is an area at risk of ulceration.
Source: SAME ISCMSP.
consequent to complications from Charcot arthropathy 
or by maintenance of a foot that was incapable of 
supporting the body’s weight while walking (with use 
of crutches or a wheelchair).
Lesser amputations involving only the forefoot (of 
the toes or rays, or transmetatarsal or at the level of 
the Lisfranc joint) were not considered to be relevant 
in the final evaluation, unless they were directly rela-
ted to Charcot arthropathy with the midfoot affected. 
This criterion was used when the triggering factor 
for amputation of the forefoot was the presence of 
infected or ischemic ulcers.
Deaths caused by alterations relating to Charcot 
arthropathy were considered to be an unsatisfactory 
result from the treatment.
Risk factors such as bilaterality, smoking, drinking, 
interval between onset of diabetes and appearance of 
Charcot arthropathy, insulin use, vascular disorders, 
sensory disorders, stage of evolution and initial loca-
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in order to try to save the foot from possible amputa-
tion(19). After the reconstructive surgery, a prolonged 
period of immobilization with TCC is indicated, until 
bone consolidation or stable ankylosis of the foot or 
ankle is achieved.
Amputation of the foot may be indicated in the 
presence of severe infection of soft tissue or bone tis-
sue, or in cases in which there is significant deformity 
with concomitant insufficient circulation of the feet, 
or after failure of surgical treatment(21-24).
Evaluation of the results after treatment 
To evaluate the results, we divided the treatment of 
Charcot arthropathy of the midfoot according to two 
possible types of outcome: 1) satisfactory, characterized 
by preservation of a functional foot capable of supporting 
the body’s weight for independent walking, even if this 
required use of an orthosis of AFO type or a walking 
stick; 2) unsatisfactory, characterized by amputation 
MIDFOOT CHARCOT ARTHROPATHY IN DIABETIC PATIENTS: COMPLICATION OF AN EPIDEMIC DISEASE 
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tion affected by Charcot arthropathy were correlated 
in order to try to assess the possible influence of these 
factors on the result from treating the disease.
For the statistical analysis, the SPSS 13.0 software 
for Windows was used. Descriptive measurements of 
the quantitative variables and the absolute and relative 
frequencies of the qualitative variables were obtai-
ned. The chi-square or Fisher exact test was used to 
compare qualitative variables and Student’s t test was 
used to compare qualitative variables with quantita-
tive variables.
The possible costs resulting from surgical treat-
ment were inferred indirectly by taking into conside-
ration the number of operations performed on patients 
in a severe condition.
RESULTS
Our sample was formed by 88 patients, of whom 
22 was affected bilaterally, thus totaling 110 extremi-
ties. The mean age of the 35 female patients and 53 
male patients at the start of the outpatient follow-up 
was 59 years (ranging from 32 to 87 years) and the 
mean length of follow-up was 21 months (ranging 
from 13 to 73 months).
At the time when the 88 patients arrived at our 
outpatient clinic, the anatomical location of the le-
sions presented the following distribution: TM joints 
(Brodsky type I) in 45 patients (51%); TN, CC and 
ST joints (Brodsky type II) in 20 (23%); and midfoot 
joints with extension to the hindfoot (Trepman type 
IV) in 23 patients (26%).
The stage of evolution of the disease at the time of 
the first consultation had the following distribution: 
in 41 patients (47%), the lesion was in the initial pha-
se of bone fragmentation (Eichenholtz type I); in 17 
(19%), it was in the consolidation phase (Eichenholtz 
type II); and in 30 (34%), it was in the late phase of 
sequelae (Eichenholtz type III).
Through correlating the anatomical location with 
the stage of evolution of the Charcot arthropathy, 
we observed that out of the 45 patients with the TM 
joint affected (Brodsky I), 22 (49%) presented the 
disease in the evolutional phase of fragmentation 
(Eichenholtz type I); six (13%) were in the conso-
lidation phase (Eichenholtz type II); and 17 (38%) 
were in the phase of sequelae (Eichenholtz type III) 
(Figure 4). In this group of 45 patients with the TM 
joint affected, closed treatment was performed suc-
cessfully in 35 (78%). Some type of surgery was re-
quired for 10 patients (22%), distributed thus: plantar 
exostectomy in four patients; modeling arthrodesis 
in another four; and amputation of the extremity in 
another two (Figures 5 and 6).
Among the 20 patients who presented Charcot ar-
thropathy affecting the TN, CC and ST joints (Bro-
dsky type II), nine (45%) had the disease in the evo-
lutional phase of fragmentation (Eichenholtz type I); 
four (20%) were in the evolutional phase of consoli-
dation (Eichenholtz type II); and seven (35%) were in 
the phase of sequelae (Eichenholtz type III) (Figure 
4). In this group of 20 patients with the TN, CC and 
ST joints affected, closed treatment was successfully 
performed in 12 (60%). Some type of surgery was re-
quired for eight patients (40%), distributed thus: plan-
tar exostectomy in four patients; modeling arthrodesis 
in another three; and amputation of the extremity in a 
single patient (Figures 5 and 6).
Among the 23 patients who presented Charcot 
arthropathy involving the midfoot and extending to 
the hindfoot (Trepman type IV), ten (43%) had the 
disease in the evolutional phase of fragmentation (Ei-
chenholtz type I); seven (30%) were in the evolutional 
phase of consolidation (Eichenholtz type II); and six 
(26%) were in the phase of sequelae (Eichenholtz 
Figure 4 – Distribution of the 88 patients with Charcot arthroplasty in relation 
to the anatomical location of the lesions and the evolutional stage of the 
disease. The numerical values represent the numbers of patients; the size 
of the circles is proportional to the number of patients affected.
TM: tarsometatarsal; TN: talonavicular; CC: calcaneocuboid; ST: subtalar. Source: SAME ISCMSP.
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type III) (Figure 4). In this group of 23 patients with 
the midfoot affected and extension to the hindfoot, 
conservative treatment was successfully performed in 
seven (30%). Some type of surgery was required for 
16 patients (70%), distributed thus: modeling arthro-
desis in 15 patients and amputation of the extremity 
in a single patient (Figures 5 and 6).
Analysis on seven risk factors (1 – age; 2 – type of 
diabetes; 3 – insulin use; 4 – bilaterality; 5 – smoking; 
6 – drinking; and 7 – vascular diseases) that have 
all been associated with higher incidence of com-
plications in treating Charcot arthropathy in diabetic 
patients, we found that among 75 of the 88 patients 
(85%), whose results from the treatment were consi-
dered satisfactory, the mean age was 59 years; 68 of 
these 75 patients (91%) presented type II diabetes; 
47 (63%) were using insulin to clinically control the 
disease; 17 (23%) were affected bilaterally; 22 (29%) 
were smokers; 19 (25%) were drinkers; and 36 (48%) 
presented clinical signs of vascular disease. Among 
the group of 13 of the 88 patients (15%), whose ou-
tcome was considered unsatisfactory, the mean age 
Figure 5 – Distribution of the 88 patients with Charcot arthroplasty in relation 
to the anatomical location of the lesions and the type of treatment used. The 
numerical values represent the numbers of patients; the size of the circles 
is proportional to the number of patients affected.
TM: tarsometatarsal; TN: talonavicular; CC: calcaneocuboid; ST: subtalar. Source: SAME ISCMSP.
Figure 6 – Distribution of the 88 patients with Charcot arthroplasty in relation 
to the evolutional stage of the disease and the type of treatment used. The 
numerical values represent the numbers of patients; the size of the circles 
is proportional to the number of patients affected. 
Source: SAME ISCMSP.
was 62 years; 12 of these 13 patients (92%) presented 
type II diabetes; seven (63%) were using insulin to 
clinically control the disease; five (38%) were affec-
ted bilaterally; six (29%) were smokers; five (38%) 
were drinkers; and five (38%) presented clinical signs 
of vascular disease. The sample size was insufficient 
for us to identify statistical significance in all the as-
sociated factors, but we observed a tendency towards 
unsatisfactory results among the patients bilaterally 
affected by Charcot arthropathy who were smokers 
or drinkers.
In correlating the anatomical locations of the 
lesions (types I, II or IV) with the outcome from 
the treatment (satisfactory or unsatisfactory), we 
found that among the 75 patients whose results were 
considered satisfactory, the lesions had the following 
distribution: TM joints (Brodsky type I) in 39 patients 
(52%); TN, CC and ST joints (Brodsky type II) in 17 
(23%); and lesions of mixed type, extending from the 
midfoot to the hindfoot (type IV) in 19 (25%). In the 
group of 13 patients whose results from the treatment 
were considered unsatisfactory, the anatomical 
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distribution of the lesions in the extremities was as 
follows: TM joint (Brodsky type I) in six patients 
(46%); TN, CC and ST joints (Brodsky type II) in 
three (23%); and midfoot affected primarily with 
extension to the hindfoot (Trepman type IV) in four 
(31%). No significant difference was seen through 
correlating the anatomical distribution of the lesions 
with the outcome from the treatment (satisfactory or 
unsatisfactory).
From correlating the evolutional stage of Charcot 
arthropathy (as classified by Eichenholtz) with the fi-
nal outcome from the treatment (satisfactory or unsa-
tisfactory), we found that in the group of 75 patients 
whose final result was considered to be satisfactory, 
35 (47%) were in the initial phase of fragmentation 
(Eichenholtz stage I); 14 (19%) were in the bone 
consolidation phase (Eichenholtz stage II); and 26 
(35%) were in the phase of sequelae (Eichenholtz 
stage III). In the group of 13 patients whose final 
result was considered unsatisfactory, six (46%) were 
in stage I; three (23%) in stage II; and four (31%) 
in stage III. There was no significant difference in 
correlating the distribution of the evolutional stage 
of Charcot arthropathy with the outcome from the 
treatment (satisfactory or unsatisfactory.
In correlating the results with the type of treat-
ment used, we found that closed treatment, which 
was used for 54 of the 88 patients (61%) of our 
sample, presented results that were considered sa-
tisfactory in 49 cases (91%) and unsatisfactory in 
five (9%). In relation to surgical treatment, which 
was performed for 34 of the 88 patients (39%), the 
outcome was satisfactory in 26 cases (76%) and un-
satisfactory in eight (24%). We observed a tendency 
towards satisfactory results among the patients who 
received closed treatment, compared with those who 
required some type of surgery, but it was not possible 
to identify statistical significance because the sample 
size was insufficient.
In comparing the type of surgery performed with 
the final result, we observed that all of the eight pa-
tients who only underwent exostectomy of a plantar 
bone prominence presented satisfactory results. On 
the other hand, among the 23 patients who underwent 
modeling arthrodesis, satisfactory results were achie-
ved in 18 (78%). One of the five patients whose re-
sults from modeling arthrodesis were considered un-
satisfactory required amputation of the extremity; two 
patients remained with the affected limb deformed, 
unstable and incapable of bearing body weight or fit-
ting with an orthosis; and the other two patients died 
due to complications such as postoperative infection. 
For three patients, amputation of the extremity was 
indicated primarily as the form of treatment.
In subdividing the 88 patients of our sample ac-
cording to the extent of Chart arthropathy, we esta-
blished two distinct groups: group I – lesion located 
exclusively in the midfoot (Brodsky types I and II), 
in 65 patients (74%); and group II – lesion extending 
from the midfoot to the hindfoot (Trepman type IV), 
in 23 patients (26%). Comparing the treatment ou-
tcomes between these two groups, we did not find 
any statistically significant difference with regard 
to satisfactory results, which were achieved in the 
cases of 54 of the 65 patients (86%) in whom the 
lesion was restricted to the midfoot (group I) and 
in 19 of the 23 patients (83%) in whom the lesions 
affected both the midfoot and the hindfoot (group 
II). However, regarding the need for surgery du-
ring the course of the treatment, we observed that in 
group I, only 18 of the 65 patients (28%) needed to 
be operated, whereas in group II surgery was needed 
for 16 of the 23 patients (70%). This difference was 
statistically significant (p < 0.001), thus demons-
trating that there was a need for surgery during the
treatment among the patients whose lesions extended 
from the midfoot to the hindfoot, for a satisfactory 
result to be obtained.
In analyzing the type of surgery needed during the 
course of the treatment, in the group of 65 patients 
in group I (affected exclusively in the midfoot), 
primary amputation was indicated in two patients; 
exostectomy of a plantar bone prominence was suc-
cessfully performed in eight patients; and modeling 
arthrodesis of the extremity was necessary in ano-
ther eight patients, with success in six cases. In the 
two patients who underwent modeling arthrodesis 
whose outcome was unsatisfactory, one developed 
an unstable deformity of the extremity and the other 
died due to complications relating to postoperative 
infection. Out of the total of 18 patients who were 
exclusively affected in the midfoot and underwent 
surgical treatment, the outcome was considered to 
be satisfactory in 14 (78%).
In the group of 23 patients who were affected in 
the midfoot with extension to the hindfoot (group II), 
Rev Bras Ortop. 2012;47(5):616-25
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surgical treatment was necessary in 16 (70%). Prima-
ry amputation of the extremity was indicated for one 
patient and modeling arthrodesis for the other 15. The 
final result was considered satisfactory in the cases 
of 12 of these 16 patients (75%). Among the three 
patients who underwent modeling arthrodesis and 
had unsatisfactory outcomes, one developed unstable 
deformity of the extremity and the other two died due 
to complications relating to postoperative infection. 
In comparing the patients with lesions restricted to 
the midfoot (group I) with those whose lesions ex-
tended from the midfoot to the hindfoot (group II), 
we did not observe any statistically significant di-
fference in relation to the result from the treatment. 
However, to attain the same number of satisfactory 
results as obtained in group I, a significantly greater 
number of surgical procedures were needed among 
the patients whose midfoot and hindfoot were both 
affected (group II).
DISCUSSION
The sample of 88 patients (110 extremities) in the 
present study was derived from the register of all of 
the 580 patients who were being followed up at our 
specialized outpatient clinic and were treated for foot 
conditions relating to late-stage complications from 
diabetes. Because our clinic is at a university hospital 
that provides tertiary-level orthopedic care and is a 
referral center for a large part of the city of São Paulo, 
we attend large numbers of previously screened pa-
tients presenting severe complications. The diagnosis 
of Charcot arthropathy was confirmed by means of 
radiographs on the feet of 174 patients, i.e. approxi-
mately 30% of all the diabetic patients followed up 
at out outpatient clinic. Of these, 88 patients fulfilled 
the selection and inclusion criteria for this study, thus 
corresponding to approximately 51% of all of the ca-
ses of Charcot arthropathy identified at out clinic and 
15% of all the patients with late complications from 
diabetes in their feet.
The Department of Orthopedics and Traumatology 
of the Irmandade da Santa Casa de Misericórdia de 
São Paulo is located in the central region of Greater 
Grande São Paulo, an area with 18 million inhabi-
tants(25), and it attends patients who mostly do not 
have health insurance. Thus, it can be considered that 
our sample depicted a relatively significant portion of 
the diabetic patients who sought the public healthca-
re system for treatment of severe problems affecting 
their feet.
In analyzing the characteristics of the diabetic pa-
tients with Charcot arthropathy that primarily affected 
the midfoot and those whose disease also extended 
to the hindfoot, we identified the following patterns: 
elderly patients whose mean age was around 59 years; 
long duration of the disease, with a mean reaching 12 
years; predominance of type II disease (in 91% of the 
cases); and high number of insulin-dependent patients 
(62%). These data, when added to the socioeconomic 
profile of the patients attended at our institution (low 
educational level and low income), give rise to spe-
cial concern regarding the financial impact on public 
health. Charcot arthroplasty is one of the severe late-
-stage manifestations of diabetes and, in conjunction 
with other complications such as nephropathy, reti-
nopathy and cardiocirculatory disorders(2), it has the 
potential to cause high expenditure, thus consuming 
enormous amounts of financial resources destined for 
public health.
In our sample, 32% of the patients were smokers 
and 27% were drinkers. These are vices that have 
been widely recognized to have an unfavorable im-
pact when associated with diabetes(26). We believe 
that the misinformation that is typically correlated 
with patients who smoke and drink can be combated 
through educational programs.
Some degree of peripheral vascular disease was 
identified in 47% of the patients in our series. In the 
great majority of the cases, there was no evident cli-
nical repercussion, given that our service receives 
patients who were previously screened and predomi-
nantly present orthopedic conditions.
In our series, 22 (25%) of the 88 patients presen-
ted bilateral occurrence of Charcot arthropathy. The 
treatments for these patients resulted in unfavorable 
outcomes in five cases (23%), thus showing a ten-
dency towards worse results than among the patients 
with unilateral lesions. In the literature, it has been 
shown that the results from treatments among patients 
affected bilaterally by Charcot arthropathy are worse 
than the outcomes in unilateral cases(16,27,28). However, 
in our series, this could not be demonstrated due to 
the insufficient sample size.
Use of a systematized protocol for administering 
treatment for Charcot arthropathy affecting the mi-
dfoot involves minimizing the damage and reducing 
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the risks of complications. Deformities, foot and ankle 
joint instability and plantar bone prominences are of-
ten associated with elevated pressure during the wei-
ght-bearing phase of gait. As a consequence, ulcers 
and secondary infections tend to arise, which may put 
the patient’s extremity fatally at risk of amputation.
In our series, we found that the hindfoot and 
ankle were affected secondarily from the typical 
lesions of Charcot arthropathy that began in the 
midfoot. We believe that slowness in identifying 
osteoarticular lesions, both in TM joints (Brodsky 
type I) and in TN, CC and ST joints (Brodsky type 
II), especially delayed the start of treatment with 
TCC. Mistaken and late diagnosis were extremely 
common among the patients who sought attendance 
at our outpatient clinic, and the great majority of 
them reported that there had been a long interval 
between the appearance of the first symptoms and 
the definitive diagnosing of Charcot arthropathy. 
Because of diagnostic failures and late starts to tre-
atment, we found that 26% of the patients in our 
series began outpatient treatment at an advanced 
stage of the disease, with lesion locations that had 
already extended from the midfoot to the hindfoot 
(Trepman type IV). We attribute this progression of 
the disease to the prolonged period during which 
the patients continued to bear weight on the lower 
extremity without any type of protection. This cer-
tainly contributed towards increasing the osteoar-
ticular destruction and towards progression of the 
deformities, thus worsening the clinical condition 
and making the treatment more difficult.
In assessing the efficacy of the treatment protocol 
for Chart arthropathy affecting the midpoint that was 
used in this study, we noted that after a mean length of 
follow-up of 21 months, 75 of the 88 patients (85%) 
presented satisfactory results, in which it was possible 
to achieve a plantigrade foot that was stable or could 
be accommodated in a molded orthosis of AFO type, 
with weight-bearing during gait. The anatomical 
location of the lesion (restricted to the midfoot or 
extending to the hindfoot), the evolutional stage of 
the disease at the time when the patient arrived at the 
outpatient clinic (Eichenholtz stages I, II or III) and the 
type of treatment needed (closed or surgical) did not 
influence the result from the treatment (satisfactory or 
unsatisfactory). However, we found that a significantly 
greater proportion (70%) of the patients whose 
osteoarticular lesions extended from the midfoot to 
the hindfoot (Trepman type IV) required surgery than 
among the patients whose Charcot arthropathy was 
restricted to the midfoot (28%).
Surgical indication for treating the problems rela-
ting to Charcot arthropathy was not optional among 
the criteria used in our protocol. Selection of the pa-
tients who were candidates for surgery followed the 
order of severity of the lesions. Plantar exostectomy 
was the simplest procedure, and was indicated for 
treating the bone prominences that were responsible 
for recurrent ulceration(19). All the eight patients in 
our series who underwent this type of procedure 
had favorable evolution. Among the patients with 
severe unstable deformities affecting the midfoot or 
hindfoot who were incapable of plantigrade weight-
-bearing and were in imminent danger of developing 
pressure ulcers, or already presented recurrent ul-
ceration, modeling arthrodesis was indicated with 
the objective of avoiding possible amputation of 
the extremity(21-24). In our sample, modeling arthro-
desis was successful in 18 of the 23 patients, thus 
attaining a salvage rate of 78% of the extremities 
operated. Two of the patients whose results were 
unsatisfactory after the salvage attempt using mo-
deling arthrodesis died due to complications such 
as postoperative infection. In another two patients, 
both the deformity and the instability of the extre-
mity persisted, thus impeding weight-bearing on the 
limb during gait; however, these patients refused to 
undergo amputation.
The worldwide incidence of diabetes is expec-
ted to increase over the coming years, especially in 
emerging countries(3). In addition, improved clinical 
control over the disease has promoted greater life ex-
pectancy among diabetic patients, thus prolonging the 
period of exposure to the risks of late complications 
from the disease(4,5). In this light, public healthcare 
bodies need to prioritize attention to basic education 
among the patients; to special programs for preven-
tion and treatment of diabetes and its late-stage com-
plications; to the infrastructure and preparedness of 
healthcare units; and to early treatment for lesions in 
feet caused by Charcot arthropathy. In this manner, 
effective directing of resources might avoid waste due 
to complex, prolonged and burdensome treatments 
that very often have poor results.
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CONCLUSIONS
The epidemiological profile of diabetic patients 
with Charcot arthropathy affecting the midfoot is 
characterized by manifestation of the disease in the 
third age, presence of type II diabetes and chronic 
insulin use, with osteoarticular lesions originating 
in the midfoot and progressively extending to the 
hindfoot, due to delayed diagnosis and a late start for 
appropriate treatment.
In the great majority of our cases (85%), the re-
sult from our treatment protocol for Charcot arthro-
pathy affecting the midfoot was satisfactory. Howe-
ver, among the patients whose lesion extended from 
the midfoot to the hindfoot (type IV), the number of 
operations needed to attempt to preserve the extremi-
ty was significantly greater than among the patients 
whose Charcot arthropathy was restricted to the mi-
dfoot (types I and II).
Rev Bras Ortop. 2012;47(5):616-25
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